Clinical genomics approaches the challenges of integrating novel insights obtained via next generation sequencing advances with clinical insights of direct relevance and benefit to patients. How the genomic differences influence our health provides important information for pharmacogenomics to facilitate drug discovery and development, as well as to assess the efficacy of medications in treatment modalities. Combining patient genome, transcriptome, and DNA methylome data can be used to inform diagnosis and prognostic indicators. Understanding mutations and predispositions to disease will likely allow for early interventions as well as targeted and personalised regimes.
Clinical Genomics Domain Leader - Associate Professor Paul Leo
Associate Professor Paul Leo is the Deputy Director of Genomics at the Australian Translational Genomics Centre. The Australian Translational Genomics Centre is a collaborative project between Princess Alexandria Hospital, Queensland Pathology and QUT that provides personalised medicine to cancer patients using Next Generation sequencing technologies. In that capacity Paul supervises five bioinformaticians and liaises with clinical staff at the Princess Alexandria Hospital on clinical report interpretation. Paul’s research interests focus on the application of genomic technologies to human diseases. This has led to the discovery of new causative genes in monogenic diseases and genes that contribute to disease risk in cervical cancer, osteoporosis and ankylosing spondylitis. Currently his research interests include the identification for driver genes in non-melanoma skin cancers and blood cancers.
View Associate Professor Paul Leo’s profile